Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

doi:10.1158/1078-0432.CCR-17-1423

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2017

Craddock Charles F, Houlton Aimee E, Quek Lynn Swun, Ferguson Paul, Gbandi Emma, Roberts Corran, Metzner Marlen, Garcia-Martin Natalia, Kennedy Alison, Hamblin Angela, Raghavan Manoj, Nagra Sandeep, Dudley Louise, Wheatley Keith, McMullin Mary Frances, Pillai Srinivas P, Kelly Richard J, Siddique Shamyla, Dennis Michael, Cavenagh Jamie D, Vyas Paresh

Abstract excerpt

Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are defined. Co-administration of histone deacetylase inhibitors, such as vorinostat (VOR), is reported to improve the clinical activity of AZA, but this has not been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Cyclin-Dependent Kinase Inhibitor p18

Share to Drug Administration Schedule

Share to Histone Deacetylase Inhibitors

Share to Hydroxamic Acids

Share to Vorinostat

Source

Open in PubMed

Identifiers

PMID: 28765326
DOI: 10.1158/1078-0432.CCR-17-1423

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.PMID 28765326Read ↗

Translational Research on Azacitidine Post- Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Semantic proximity Read ↗

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity Read ↗

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity Read ↗

Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).Semantic proximity Read ↗

HDAC Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careSemantic proximity Read ↗

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)Semantic proximity Read ↗

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.Semantic proximity Read ↗

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLSemantic proximity Read ↗

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular MechanismsSemantic proximity Read ↗

Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemiaSemantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.